Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly tested in patients with advanced lymphoma. Following treatment, many of those patients are likely to be candidates for allogeneic hematopoietic stem cell transplant (HSCT). However, the safety and efficacy of HS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Merryman, Reid W., Kim, Haesook T., Zinzani, Pier Luigi, Carlo-Stella, Carmelo, Ansell, Stephen M., Perales, Miguel-Angel, Avigdor, Abraham, Halwani, Ahmad S., Houot, Roch, Marchand, Tony, Dhedin, Nathalie, Lescaut, Willy, Thiebaut-Bertrand, Anne, François, Sylvie, Stamatoullas-Bastard, Aspasia, Rohrlich, Pierre-Simon, Labussière Wallet, Hélène, Castagna, Luca, Santoro, Armando, Bachanova, Veronika, Bresler, Scott C., Srivastava, Amitabh, Kim, Harim, Pesek, Emily, Chammas, Marie, Reynolds, Carol, Ho, Vincent T., Antin, Joseph H., Ritz, Jerome, Soiffer, Robert J., Armand, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5345733/
https://ncbi.nlm.nih.gov/pubmed/28073785
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-738385
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados